References

pulmo

Пульмонология

PULMONOLOGIYA

0869-01892541-9617

Scientific and Practical Journal “PULMONOLOGIYA” LLC

10.18093/0869-0189-2010-1-13-65

pulmo-1611

Research Article

Статьи

Показатели, оцениваемые в фармакологических исследованиях ХОБЛ: от легочной функции до биомаркеров

Казолла

М. .

noemail@neicon.ru

Мак-Ни

В. .

noemail@neicon.ru

Мартинес

Ф. Дж.

noemail@neicon.ru

Рабе

К. Ф.

noemail@neicon.ru

Франчиози

Л. Дж.

noemail@neicon.ru

Барнс

П. Дж.

noemail@neicon.ru

Брусаско

В. .

noemail@neicon.ru

Бурдж

П. С.

noemail@neicon.ru

Калверлей

П. М.

noemail@neicon.ru

Селли

Б. Р.

noemail@neicon.ru

Джонс

П. В.

noemail@neicon.ru

Малер

Д. А.

noemail@neicon.ru

Мейк

Б. .

noemail@neicon.ru

Миравиттлс

М. .

noemail@neicon.ru

Пейдж

С. П.

noemail@neicon.ru

Паланьи

П. .

noemail@neicon.ru

Парр

Д. .

noemail@neicon.ru

Пистолези

М. .

noemail@neicon.ru

Реннард

С. И.

noemail@neicon.ru

Руттен Ван Мелькен

М. П.

noemail@neicon.ru

Стокли

Р. .

noemail@neicon.ru

Салливан

С. Д.

noemail@neicon.ru

Ведзича

Дж. А.

noemail@neicon.ru

Воутерс

Е. Ф.

noemail@neicon.ru

2010

28022010

011365

Copyright © Казолла М..., Мак-Ни В..., Мартинес Ф.Д., Рабе К.Ф., Франчиози Л.Д., Барнс П.Д., Брусаско В..., Бурдж П.С., Калверлей П.М., Селли Б.Р., Джонс П.В., Малер Д.А., Мейк Б..., Миравиттлс М..., Пейдж С.П., Паланьи П..., Парр Д..., Пистолези М..., Реннард С.И., Руттен Ван Мелькен М.П., Стокли Р..., Салливан С.Д., Ведзича Д.А., Воутерс Е.Ф., 2010

2010

Казолла М..., Мак-Ни В..., Мартинес Ф.Д., Рабе К.Ф., Франчиози Л.Д., Барнс П.Д., Брусаско В..., Бурдж П.С., Калверлей П.М., Селли Б.Р., Джонс П.В., Малер Д.А., Мейк Б..., Миравиттлс М..., Пейдж С.П., Паланьи П..., Парр Д..., Пистолези М..., Реннард С.И., Руттен Ван Мелькен М.П., Стокли Р..., Салливан С.Д., Ведзича Д.А., Воутерс Е.Ф.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.pulmonology.ru/pulm/article/view/1611

References1

Committee for Proprietary Medicinal Products. Points to consider on clinical investigation of medicinal products in the chronic treatment of patients with chronic obstructive pulmonary disease (COPD). London; 1999. CPMP / EWP / 562 / 98.

Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.

Edwards N. A framework for future trials: Guidelines on developing COPD drugs. Good Clin. Pract. J. 2004; 11: 1-5.

Jones P.W., Agusti A.G.N. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 822-832.

Celli B.R., Calverley P.M., Rennard S.I. et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1546-1554.

ZuWallack R.L., Haggerty M.C., Jones P. Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. Am. J. Med. 2004; 117 (suppl. 12A): 49S-59S.

Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26: 319-338.

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am. Rev. Respir. Dis. 1991; 144: 1202-1218.

Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. 1993; 16 (suppl. 16): 5-40.

Pellegrino R., Viegi G., Brusasco V. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 2005; 26: 948-968.

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI / WHO Workshop Report 2005. www.goldcopd.com Date last accessed: November 2, 2007.

Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J. A. M. A. 1994; 272: 1497-1505.

Anonymous. GSK's Ariflo gets US approvable letter for COPD. Scrip Wld Pharmaceut. News 2003; 21: Oct. 31, 2898.

Swanney M.P., Jensen R.L., Crichton D.A. et al. FEV6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am. J. Respir. Crit. Care Med. 2000; 162: 917-919.

Hankinson J.L., Crapo R.O., Jensen R.L. Spirometric reference values for the 6-s FVC maneuver. Chest 2003; 124: 1805-1811.

Garcia-Rio F., Pino J.M., Dorgham A. et al. Spirometric reference equations for European females and males aged 65-85 yrs. Eur. Respir. J. 2004; 24: 397-405.

Vandevoorde J., Verbanck S., Schuermans D. et al. FEV1 / FEV6 and FEV6 as an alternative for FEV1 / FVC and FVC in the spirometric detection of airway obstruction and restriction. Chest 2005; 127: 1560-1564.

Akpinar-Elci M., Fedan K.B., Enright P.L. FEV6 as a surrogate for FVC in detecting airways obstruction and restriction in the workplace. Eur. Respir. J. 2006; 27: 374-377.

Pedersen O.F. FEV6: a shortcut in spirometry? Eur. Respir. J. 2006; 27: 245-247.

Vandevoorde J., Verbanck S., Schuermans D. et al. Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1 / FEV6 and FEV6. Eur. Respir. J. 2006; 27: 378-383.

Bang K.M., Gergen P.J., Kramer R., Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536-540.

Neas L.M., Schwartz J. Pulmonary function levels as predictors of mortality in a national sample of US adults. Am. J. Epidemiol. 1998; 147: 1011-1018.

Knuiman M.W., James A.L., Divitini M.L. et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann. Epidemiol. 1999; 9: 297-306.

Schunemann H.J., Dorn J., Grant B.J. et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 656-664.

Stavem K., Aaser E., Sandvik L. et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur. Respir. J. 2005; 25: 618-625.

Wolkove N., Dajczman E., Colacone A., Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.

Hay J.G., Stone P., Carter J. et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. 1992; 5: 659-664.

Bauerle O., Chrusch C.A., Younes M. Mechanisms by which COPD affects exercise tolerance. Am. J. Respir. Crit. Care Med. 1998; 157: 57-68.

O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.

Ferrer M., Alonso J., Prieto L. et al. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur. Respir. J. 1996; 9: 1160-1166.

Hajiro T., Nishimura K., Tsukino M. et al. Comparison of discriminative properties among disease-specific questionnaires for measuring healthrelated quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 785-790.

Pellegrino R., Rodarte J.R., Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-1612.

Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-664.

TheNational Emphysema Treatment Trial Research Group. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. Chest 1999; 116: 1750-1761.

Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608-1613.

Aaron S.D., Vandemheen K.L., Clinch J.J. et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121: 688-696.

Niewoehner D.E., Collins D., Erbland M.L. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am. J. Respir. Crit. Care Med. 2000; 161: 1201-1205.

Parker C.M., Voduc N., Aaron S.D. et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur. Respir. J. 2005; 26: 420-428.

Cerveri I., Pellegrino R., Dore R., et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J. Appl. Physiol. 2000; 88: 1989-1995.

van Schayck C.P., Loozen J.M., Wagena E. et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. Br. Med. J. 2002; 324: 1370.

Miller M.R., Crapo R., Hankinson J. et al. General considerations for lung function testing. Eur. Respir. J. 2005; 26: 153-161.

Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26: 511-522.

Stocks J., Quanjer P.H. Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. Eur. Respir. J. 1995; 8: 492-506.

Hankinson J.L., Stocks J., Peslin R. Reproducibility of lung volume measurements. Eur. Respir. J. 1998; 11: 787-790.

O'Donnell D.E., Revill S.M., Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 770-777.

Boni E., Corda L., Franchini D. et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002; 57: 528-532.

O'Donnell D.E., Webb K.A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am. Rev. Respir. Dis. 1993; 148: 1351-1357.

O'Donnell D.E., Webb K.A., Bertley J.C. et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110: 18-27.

O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.

O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 86-94.

Diaz O., Villafranca C., Ghezzo H. et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur. Respir. J. 2000; 16: 269-275.

Marin J.M., Carrizo S.J., Gascon M. et al. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1395-1399.

Newton M.F., O'Donnell D.E., Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050.

Murciano D., Ferretti A., Boczkowski J. et al. Flow limitation and dynamic hyperinflation during exercise in COPD patients after single lung transplantation. Chest 2000; 118: 1248-1254.

Casanova C., Cote C., de Torres J.P. et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591-597.

Ingenito E.P., Loring S.H., Moy M.L. et al. Physiological characterization of variability in response to lung volume reduction surgery. J. Appl. Physiol. 2003; 94: 20-30.

Tantucci C., Duguet A., Similowski T. et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1998; 12: 799-804.

Maltais F., Hamilton A., Marciniuk D. et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.

O'Donnell D.E. Is sustained pharmacologic lung volume reduction now possible in COPD? Chest 2006; 129: 501-503.

Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.

van Noord J.A., Aumann J.L., Janssens E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.

Stevenson N.J., Walker P.P., Costello R.W., Calverley P.M. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 1510-1516.

Duranti R., Filippelli M., Bianchi R. et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009-2014.

Dolmage T.E., Goldstein R.S. Repeatability of inspiratory capacity during incremental exercise in patients with severe COPD. Chest 2002; 121: 708-714.

Yan S., Kaminski D., Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 156: 55-59.

American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am. J. Respir. Crit. Care Med. 1995; 152: 2185-2198.

Cramer D. Standardization of the measurement of transfer factor. Eur. Respir. J. 1993; 6: 1577-1578.

Macintyre N., Crapo R.O., Viegi G. et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005; 26: 720-735.

Paoletti P., Viegi G., Pistelli G. et al. Reference equations for the single-breath diffusing capacity. A cross-sectional analysis and effect of body size and age. Am. Rev. Respir. Dis. 1985; 132: 806-813.

Knudson R.J., Kaltenborn W.T., Knudson D.E., Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am. Rev. Respir. Dis. 1987; 135: 805-811.

Roca J., Rodriguez-Roisin R., Cobo E. et al. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. Am. Rev. Respir. Dis. 1990; 141: 1026-1032.

Cerveri I., Dore R., Corsico A. et al. Assessment of emphysema in COPD: a functional and radiologic study. Chest 2004; 125: 1714-1718.

Goldberg R., Hillberg R., Reinecker L., Goldstein R. Evaluation of patients with severe pulmonary disease before and after pulmonary rehabilitation. Disabil. and Rehabil. 2004; 26: 641-648.

Trow T.K. Lung-volume reduction surgery for severe emphysema: appraisal of its current status. Curr. Opin. Pulm. Med. 2004; 10: 128-132.

Meyers B.F., Yusen R.D., Guthrie T.J. et al. Results of lung volume reduction surgery in patients meeting a national emphysema treatment trial high-risk criterion. J. Thorac. Cardiovasc. Surg. 2004; 127: 829-835.

Wanger J., Irvin C. Comparability of pulmonary function results from 13 laboratories in a metropolitan area. Respir. Care 1991; 36: 1375-1382.

Gaensler E.A., Smith A.A. Attachment for automated single breath diffusing capacity measurement. Chest 1973; 63: 136-145.

Punjabi N.M., Shade D., Patel A.M., Wise R.A. Measurement variability in single-breath diffusing capacity of the lung. Chest 2003; 123: 1082-1089.

Hathaway E.H., Tashkin D.P., Simmons M.S. Intraindividual variability in serial measurements of DL,CO and alveolar volume over one year in eight healthy subjects using three independent measuring systems. Am. Rev. Respir. Dis. 1989; 140: 1818-1822.

Bolliger C.T., Koegelenberg C.F., Kendal R. Preoperative assessment for lung cancer surgery. Curr. Opin. Pulm. Med. 2005; 11: 301-306.

Schluchter M.D., Stoller J.K., Barker A.F. et al. Feasibility of a clinical trial of augmentation therapy for a1-antitrypsin deficiency. The a1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med. 2000; 161: 796-801.

Stoller J.K., Snider G.L., Brantly M.L. et al. American Thoracic Society / European Respiratory Society Statement: Standards for the diagnosis and management of individuals with a1-antitrypsin deficiency. Pneumologie 2005; 59: 36-68.

Eaton T., Rudkin S., Garrett J.E. The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy. Respir. Med. 2001; 95: 655-660.

Fajac I., Texereau J., Rivoal V. et al. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults. Eur. Respir. J. 1998; 11: 712-715.

Williams A.J. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. Br. Med. J. 1998; 317: 1213-1216.

Raff H. The significance of the blood gas analyzer. J. Appl. Physiol. 2004; 97: 1597-1598.

Severinghaus J.W. First electrodes for blood PO2 and PCO2 determination. J. Appl. Physiol. 2004; 97: 1599-1600.

Aoyagi T. Pulse oximetry: its invention, theory, and future. J. Anesth. 2003; 17: 259-266.

Jubran A. Pulse oximetry. Intensive Care Med. 2004; 30: 2017-2020.

Sinex J.E. Pulse oximetry: principles and limitations. Am. J. Emerg. Med. 1999; 17: 59-67.

Welch J. Pulse oximeters. Biomed Instrum Technol 2005; 39: 125-130.

Cerveri I., Zoia M.C., Fanfulla F. et al. Reference values of arterial oxygen tension in the middle-aged and elderly. Am. J. Respir. Crit. Care Med. 1995; 152: 934-941.

Hardie J.A., Vollmer W.M., Buist A.S. et al. Reference values for arterial blood gases in the elderly. Chest 2004; 125: 2053-2060.

Soler-Cataluña J.J., Martínez-García M.A., Román Sánchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.

Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234-241.

Gay P.C. Chronic obstructive pulmonary disease and sleep. Respir. Care 2004; 49: 39-51.

Littner M.R. Portable monitoring in the diagnosis of the obstructive sleep apnea syndrome. Semin. Respir. Crit. Care Med. 2005; 26: 56-67.

Datta D., Vitale A., Lahiri B., ZuWallack R. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124: 844-849.

Sans-Torres J., Domingo C., Moron A. et al. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia. Respir. Med. 2003; 97: 599-605.

100

Cazzola M., Santus P., Matera M.G. et al. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. Respir. Med. 2003; 97: 458-462.

101

Cazzola M., Santus P., di Marco F. et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir. Med. 2003; 97: 453-457.

102

Jaen Díaz J.I., de Castro M.C., Cordero G.B. et al. Effectiveness of treatment with tiotropium in patients who suffer from COPD. Med. Clin. (Barc.) 2005; 124: 1-3.

103

Soto F.J., Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr. Opin. Pulm. Med. 2003; 9: 117-124.

104

Higgins D. Pulse oximetry. Nurs. Times 2005; 101: 34-35.

105

Lawrence J.P. Advances and new insights in monitoring. Thorac. Surg. Clin. 2005; 15: 55-70.

106

Hildick-Smith D.J., Lowe M.D., Walsh J.T. et al. Coronary angiography from the radial artery - experience, complications and limitations. Int. J. Cardiol. 1998; 64: 231-239.

107

Fabbri L.M., Hurd S.S. Global Strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur. Respir. J. 2003; 22: 1-2.

108

Arnold R., Ranchor A.V., Koeter G.H. et al. Consequences of chronic obstructive pulmonary disease and chronic heart failure: the relationship between objective and subjective health. Soc. Sci. Med. 2005; 61: 2144-2154.

109

Jones P., Lareau S., Mahler D.A. Measuring the effects of COPD on the patient. Respir. Med. 2005; 99 (suppl. 2): S11-S18.

110

Hickey A.M., Bury G., O'Boyle C.A. et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV / AIDS. Br. Med. J. 1996; 313: 29-33.

111

American Thoracic Society. Quality of Life Resource. www.atsqol.org Date last accessed: October 25, 2007.

112

Ware J.E. Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQoLA) project. J. Clin. Epidemiol. 1998; 51: 903-912.

113

Bergner M. The sickness impact profile. In: Walker S.R., ed. Quality of life: Assessment and application. Boston: M. T. P.; 1987. 79-94.

114

Hunt S.M., McEwen J. The development of a subjective health indicator. Soc. Hlth Illn. 1980; 2: 231-246.

115

Guyatt G.H., Berman L.B., Townsend M. et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.

116

Schunemann H.J., Goldstein R., Mador M.J. et al. A randomised trial to evaluate the self-administered standardized chronic respiratory questionnaire. Eur. Respir. J. 2005; 25: 31-40.

117

Puhan M.A., Behnke M., Frey M. et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomized studies. Hlth Qual. Life Outcomes 2004; 2: 1.

118

Wyrwich K.W., Tierney W.M., Wolinsky F.D. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J. Clin. Epidemiol. 1999; 52: 861-873.

119

Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145: 1321-1327.

120

Wilson C.B., Jones P.W., O'Leary C.J. et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 156: 536-541.

121

Maille A.R., Koning C.J., Zwinderman A.H. et al. The development of the ''Quality-of-life for Respiratory Illness Questionnaire (QoL-RIQ)'': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic nonspecific lung disease. Respir. Med. 1997; 91: 297-309.

122

Jacobs J.E., Maille A.R., Akkermans R.P. et al. Assessing the quality of life of adults with chronic respiratory diseases in routine primary care: construction and first validation of the 10-Item Respiratory Illness Questionnaire-Monitoring 10 (RIQMON10). Qual. Life Res. 2004; 13: 1117-1127.

123

Barley E.A., Quirk F.H., Jones P.W. Asthma health status measurement in clinical practice: validity of a new short and simple instrument. Respir. Med. 1998; 92: 1207-1214.

124

Hajiro T., Nishimura K., Jones P.W. et al. A novel, short, and simple questionnaire to measure health-related quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1874-1878.

125

Alemayehu B., Aubert R.E., Feifer R.A., Paul L.D. Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value Hlth 2002; 5: 436-441.

126

Hyland M.E., Bott J., Singh S., Kenyon C.A. Domains, constructs and the development of the breathing problems questionnaire. Qual. Life Res. 1994; 3: 245-256.

127

Hyland M.E., Singh S.J., Sodergren S.C., Morgan M.P. Development of a shortened version of the Breathing Problems Questionnaire suitable for use in a pulmonary rehabilitation clinic: a purpose-specific, disease-specific questionnaire. Qual. Life Res. 1998; 7: 227-233.

128

Carone M., Bertolotti G., Anchisi F. et al. Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Quality of Life in Chronic Respiratory Failure Group. Eur. Respir. J. 1999; 13: 1293-1300.

129

van der Molen T., Willemse B.W., Schokker S. et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Hlth Qual. Life Outcomes 2003; 1: 13.

130

Lareau S.C., Meek P.M., Roos P.J. Development and testing of the modified version of the pulmonary functional status and dyspnoea questionnaire (PFSDQ-M). Heart Lung 1998; 27: 159-168.

131

Weaver T.E., Narsavage G.L., Guilfoyle M.J. The development and psychometric evaluation of the Pulmonary Functional Status Scale: an instrument to assess functional status in pulmonary disease. J. Cardiopulm. Rehabil. 1998; 18: 105-111.

132

Nouri F.M., Lincoln N.B. An extended activities of daily living scale for stroke patients. Clin. Rehabil. 1987; 1: 301-305.

133

Okubadejo A.A., O'Shea L., Jones P.W., Wedzicha J.A. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on longterm oxygen therapy. Eur. Respir. J. 1997; 10: 1572-1575.

134

Garrod R., Bestall J.C., Paul E.A. et al. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir. Med. 2000; 94: 589-596.

135

Schunemann H.J., Goldstein R., Mador M.J. et al. Do clinical marker states improve responsiveness and construct validity of the standard gamble and feeling thermometer: a randomized multi-center trial in patients with chronic respiratory disease. Qual. Life Res. 2006; 15: 1-14.

136

Schunemann H.J., Griffith L., Stubbing D. et al. A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states. Med. Decis Making 2003; 23: 140-149.

137

Schunemann H.J., Griffith L., Jaeschke R. et al. Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J. Clin. Epidemiol. 2003; 56: 1170-1176.

138

Puhan M.A., Guyatt G.H., Montori V.M. et al. The standard gamble demonstrated lower reliability than the feeling thermometer. J. Clin. Epidemiol. 2005; 58: 458-465.

139

Kaplan R.M., Atkins C.J., Timms R. Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J. Chron. Dis. 1984; 37: 85-95.

140

EuroQol Group. EQ-5D. http://www.euroqol.org. Date last accessed: October 25, 2007.

141

Mahler D.A. Measurement of dyspnea: clinical ratings. In: Mahler D.A., ed. Dyspnea: Mechanisms, measurement and management. 2nd ed. New York: Taylor & Francis Inc.; 2005. 147-164.

142

Fletcher C.M., Elmes P.C., Fairbairn A.S., Wood C.H. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br. Med. J. 1959; 5147: 257-266.

143

Mahler D.A., Weinberg D.H., Wells C.K., Feinstein A.R. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.

144

Bestall J.C., Paul E.A., Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.

145

Hajiro T., Nishimura K., Tsukino M. et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 1185-1189.

146

Ries A.L., Kaplan R.M., Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J. Clin. Epidemiol. 1991; 44: 497-503.

147

Mahler D.A., Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 145: 467-470.

148

Mahler D.A., Ward J., Fierro-Carrion G. et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. J. COPD 2004; 1: 1-8.

149

Witek T.J. Jr., Mahler D.A. Meaningful effect size and patterns of response of the transition dyspnea index. J. Clin. Epidemiol. 2003; 56: 248-255.

150

Witek T.J. Jr., Mahler D.A. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 2003; 21: 267-272.

151

Mahler D.A., Tomlinson D., Olmstead E.M. et al. Changes in dyspnea, health status, and lung function in chronic airway disease. Am. J. Respir. Crit. Care Med. 1995; 151: 61-65.

152

Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.

153

Mahler DA. Dyspnea. In: Celli BR, ed. Pharmacotherapy of COPD. New York: Marcel Dekker Inc.; 2003. 145-158.

154

Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.

155

ZuWallack R.L., Mahler D.A., Reilly D. et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670.

156

Vincken W., van Noord J.A., Greefhorst A.P. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.

157

Donohue J.F., Kalberg C., Emmett A. et al. A short-term comparison of fluticasone propionate / salmeterol with ipratropium bromide / albuterol for the treatment of COPD. Treat Respir. Med. 2004; 3: 173-181.

158

Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.

159

Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 mg) / salmeterol (50 mg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843.

160

Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084-1091.

161

Aaron S.D., Vandemheen K.L., Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 2003; 348: 2618-2625.

162

Guyatt G.H., Townsend M., Pugsley S.O. et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am. Rev. Respir. Dis. 1987; 135: 1069-1074.

163

Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.

164

Rennard S.I., Anderson W., ZuWallack R. et al. Use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.

165

Rutten-van Mölken M., Roos B., van Noord J.A. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54: 995-1003.

166

Borg G.A. Psychophysical bases of perceived exertion. Med. Sci Sports Exerc. 1982; 14: 377-381.

167

Mahler D.A., Mejia-Alfaro R., Ward J., Baird J.C. Continuous measurement of breathlessness during exercise: validity, reliability, and responsiveness. J. Appl. Physiol. 2001; 90: 2188-2196.

168

Fierro-Carrion G., Mahler D.A., Ward J., Baird J.C. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest 2004; 125: 77-84.

169

Mahler D.A., Fierro-Carrion G., Mejia-Alfaro R. et al. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. Med. Sci. Sports Exerc. 2005; 37: 529-535.

170

Mahler D.A. Clinical measurement of dyspnea. In: Mahler D.A., ed. Dyspnea. Lung Biology in Health and Disease. New York, Marcel Dekker Inc.; 1998. 149-198.

171

Hamilton A.L., Killian K.J., Summers E., Jones N.L. Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest 1996; 110: 1255-1263.

172

Teramoto S., Fukuchi Y., Orimo H. Effects of inhaled anticholinergic drug on dyspnea and gas exchange during exercise in patients with chronic obstructive pulmonary disease. Chest 1993; 103: 1774-1782.

173

Ayers M.L., Mejia R., Ward J. et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur. Respir. J. 2001; 17: 1132-1137.

174

Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880-887.

175

Jones P.W., Quirk F.H., Baveystock C.M. Why quality of life measures should be used in the treatment of patients with respiratory illness. Monaldi Arch. Chest Dis. 1994; 49: 79-82.

176

Campbell M., Eliraz A., Johansson G. et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir. Med. 2005; 99: 1511-1520.

177

Franciosi L.G., Page C.P., Celli B.R. et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2006; 19: 189-199.

178

Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418-1422.

179

Miravitlles M., Ferrer M., Pont A. et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.

180

Doll H., Miravitlles M. Health-related QoL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 2005; 23: 345-363.

181

Schmier J.K., Halpern M.T., Higashi M.K., Bakst A. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual. Life Res. 2005; 14: 329-347.

182

Burrows B., Earle R.H. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N. Engl. J. Med. 1969; 280: 397-404.

183

Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867-874.

184

Pauwels R., Calverley P., Buist A.S. et al. COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98: 99-107.

185

Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.

186

Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (suppl. 2): 398S-401S.

187

Decramer M., Rutten-van M#ölken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552-1560.

188

Fabbri L., Beghe B., Caramori G. et al. Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. Thorax 1998; 53: 803-808.

189

Wilkinson T.M., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 1298-1303.

190

Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.

191

Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.

192

Kessler R., Stahl E., Vogelmeier C. et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest 2006; 130: 133-142.

193

Allegra L., Grassi C., Grossi E. et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. [Role of antibiotics in the treatment of acute exacerbations of chronic bronchitis: results from an Italian multicentre trial.] Ital J. Chest Dis. 1991; 45: 138-148.

194

Donaldson G.C., Seemungal T.A., Patel I.S. et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur. Respir. J. 2003; 22: 931-936.

195

Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.

196

Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur. Respir. J. 2004; 24: 206-210.

197

Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.

198

Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respir. J. 2003; 21: 68-73.

199

Gompertz S., Bayley D.L., Hill S.L., Stockley R.A. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56: 36-41.

200

Spencer S., Calverley P.M., Burge P.S., Jones P.W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur. Respir. J. 2004; 23: 698-702.

201

Miravitlles M., Murio C., Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur. Respir. J. 2001; 17: 928-933.

202

Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 842-846.

203

Miravitlles M., Murio C., Guerrero T., Gisbert R. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.

204

Garcia-Aymerich J., Monso E., Marrades R.M. et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am. J. Respir. Crit. Care Med. 2001; 164: 1002-1007.

205

Miravitlles M., Guerrero T., Mayordomo C. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 2000; 67: 495-501.

206

Antonelli I., Fuso L., De Rosa M. et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794-2800.

207

Dowson L.J., Newall C., Guest P.J. et al. Exercise capacity predicts health status in a1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2001; 163: 936-941.

208

Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. ERS Task Force on Standardization of Clinical Exercise Testing. European Respiratory Society. Eur. Respir. J. 1997; 10: 2662-2689. 209. ATS / ACCP Statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2003; 167: 211-277.

209

Saey D., Michaud A., Couillard A. et al. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 1109-1115.

210

Bowen J.B., Votto J.J., Thrall R.S. et al. Functional status and survival following pulmonary rehabilitation. Chest 2000; 118: 697-703.

211

Oga T., Nishimura K., Tsukino M. et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003; 167: 544-549.

212

Oga T., Nishimura K., Tsukino M. et al. The effects of oxitropiumbromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am. J. Respir. Crit. Care Med. 2000; 161: 1897-1901.

213

Palange P., Crimi E., Pellegrino R., Brusasco V. Supplemental oxygen and heliox: ''new'' tools for exercise training in chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2005; 11: 145-148.

214

Butland R.J., Pang J., Gross E.R. et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br. Med. J. (Clin. Res. Ed.) 1982; 284: 1607-1608.

215

Palange P., Forte S., Onorati P. et al. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J. Appl. Physiol. 2000; 88: 1715-1720.

216

Man W.D., Soliman M.G., Gearing J. et al. Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168: 562-567.

217

Fishman A., Martinez F., Naunheim K. et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059-2073.

218

Sue D.Y., Wasserman K., Moricca R.B., Casaburi R. Metabolic acidosis during exercise in patients with chronic obstructive pulmonary disease. Use of the Vslope method for anaerobic threshold determination. Chest 1988; 94: 931-938.

219

Aliverti A., Stevenson N., Dellaca R.L. et al. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004; 59: 210-216.

220

Myers J., Prakash M., Froelicher V. et al. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 2002; 346: 793-801.

221

Pellegrino R., Villosio C., Milanese U. et al. Breathing during exercise in subjects with mild-to-moderate airflow obstruction: effects of physical training. J. Appl. Physiol. 1999; 87: 1697-1704.

222

Casaburi R., Porszasz J., Burns M.R. et al. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 155: 1541-1551.

223

Martinez F.J., de Oca M.M., Whyte R.I. et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am. J. Respir. Crit. Care Med. 1997; 155: 1984-1990.

224

Somfay A., Porszasz J., Lee S.M., Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur. Respir. J. 2001; 18: 77-84.

225

O'Donnell D.E., D'Arsigny C., Webb K.A. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 892-898.

226

Palange P., Valli G., Onorati P. et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J. Appl. Physiol. 2004; 97: 1637-1642.

227

McGavin C.R., Gupta S.P., McHardy G.J. Twelve-minute walking test for assessing disability in chronic bronchitis. Br. Med. J. 1976; 1: 822-823.

228

Morgan A.D., Peck D.F., Buchanan D.R., McHardy G.J. Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br. Med. J. (Clin. Res. Ed.) 1983; 286: 171-173.

229

Sciurba F., Criner G.J., Lee S.M. et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am. J. Respir. Crit. Care Med. 2003; 167: 1522-1527.

230

Guyatt G.H., Sullivan M.J., Thompson P.J. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can. Med. Assoc. J. 1985; 132: 919-923.

231

Knox A.J., Morrison J.F., Muers M.F. Reproducibility of walking test results in chronic obstructive airways disease. Thorax 1988; 43: 388-392.

232

Gerardi D.A., Lovett L., Benoit-Connors M.L. et al. Variables related to increased mortality following outpatient pulmonary rehabilitation. Eur. Respir. J. 1996; 9: 431-435.

233

Geddes D., Davies M., Koyama H. et al. Effect of lungvolume-reduction surgery in patients with severe emphysema. N. Engl. J. Med. 2000; 343: 239-245.

234

Young J., Fry-Smith A., Hyde C. Lung volume reduction surgery (LVRS) for chronic obstructive pulmonary disease (COPD) with underlying severe emphysema. Thorax 1999; 54: 779-789.

235

Griffiths T.L., Burr M.L., Campbell I.A. et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362-368.

236

Leach R.M., Davidson A.C., Chinn S. et al. Portable liquid oxygen and exercise ability in severe respiratory disability. Thorax 1992; 47: 781-789.

237

Corris P.A., Neville E., Nariman S., Gibson G.J. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax 1983; 38: 292-296.

238

Onorati P., Antonucci R., Valli G. et al. Non-invasive evaluation of gas exchange during a shuttle walking test versus a 6-min walking test to assess exercise tolerance in COPD patients. Eur. J. Appl. Physiol. 2003; 89: 331-336.

239

Singh S.J., Morgan M.D., Scott S. et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019-1024.

240

Revill S.M., Morgan M.D., Singh S.J. et al. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54: 213-222.

241

Man W.D., Polkey M.I., Donaldson N. et al.Community pulmonary rehabilitation after hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a randomised controlled study. Br. Med. J. 2004; 329: 1209.

242

Fuld J.P., Kilduff L.P., Neder J.A. et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2005; 60: 531-537.

243

Steiner M.C., Barton R.L., Singh S.J., Morgan M.D. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax 2003; 58: 745-751.

244

Eiser N., Willsher D., Dore C.J. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir. Med. 2003; 97: 407-414.

245

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann. Intern. Med. 1980; 93: 391-398.

246

Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686.

247

Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.

248

Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809-814.

249

Camilli A.E., Robbins D.R., Lebowitz MD. Death certificate reporting of confirmed airways obstructive disease. Am. J. Epidemiol. 1991; 133: 795-800.

250

Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.

251

Sin D.D., Man S.F. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can. J. Physiol. Pharmacol. 2005; 83: 8-13.

252

Solomon S.D., Wang D., Finn P. et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110: 2180-2183.

253

Curb J.D., McTiernan A., Heckbert S.R. et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann. Epidemiol. 2003; 13 (suppl. 9): S122-S128.

254

Remington R.D. Who should code cause of death in a clinical trial? Control Clin. Trials 1984; 5: 241-244.

255

Walter S.D., Cook D.J., Guyatt G.H. et al. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group. Control Clin. Trials 1997; 18: 27-42.

256

Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1986; 133: 14-20.

257

Anthonisen N.R., Connett J.E., Enright P..L, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am. J. Respir. Crit. Care Med. 2002; 166: 333-339.

258

Celli B.R., Cote C.G., Marin J.M. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.

259

Hansen E.F., Phanareth K., Laursen L.C. et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1267-1271.

260

Landbo C., Prescott E., Lange P. et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1856-1861.

261

Mannino D.M., Buist A.S., Petty T.L. et al.Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-393.

262

Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.

263

Oga T., Nishimura K., Tsukino M. et al. Health status measured with the CRQ does not predict mortality in COPD. Eur. Respir. J. 2002; 20: 1147-1151.

264

Prescott E., Almdal T., Mikkelsen K.L. et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur. Respir. J. 2002; 20: 539-544.

265

Schols A.M., Slangen J., Volovics L., Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791-1797.

266

Soriano J.B., Vestbo J., Pride N.B. et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur. Respir. J. 2002; 20: 819-825.

267

Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-1519.

268

Mannino D.M., Ford E.S., Redd S.C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am. J. Med. 2003; 114: 758-762.

269

Cote C.G., Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur. Respir. J. 2005; 26: 630-636.

270

Imfeld S., Bloch K.E., Weder W., Russi E.W. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006; 129: 873-878.

271

Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. eds. Cost-effectiveness in health and medicine. 1-st ed. New York: Oxford University Press; 1996.

272

Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W., eds. Methods for the economic evaluation of health care programmes. 1-st ed. New York: Oxford University Press; 1997.

273

National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2004.

274

Molken M.P., Van Doorslaer E.K., Rutten F.F. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc. Sci. Med. 1992; 35: 161-175.

275

Ruchlin H.S., Dasbach E.J. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19: 623-642.

276

Rutten-van Mölken M.P., Postma M.J., Joore M.A. et al.Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir. Med. 1999; 93: 779-787.

277

Sullivan S.D., Ramsey S.D., Lee T.A. The economic burden of COPD. Chest 2000; 117 (suppl. 2): 5S-9S.

278

Strassels S.A., Smith D.H., Sullivan S.D., Mahajan P.S. The costs of treating COPD in the United States. Chest 2001; 119: 344-352.

279

Jansson S.A., Andersson F., Borg S. et al. Costs of COPD in Sweden according to disease severity. Chest 2002; 122: 1994-2002.

280

Miravitlles M., Murio C., Guerrero T., Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123: 784-791.

281

Andersson F., Borg S., Jansson S.A. et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 2002; 96: 700-708.

282

Oostenbrink J.B., Rutten-van M#ölken M.P. Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 2004; 98: 883-891.

283

van den Berg B., Brouwer W.B., Koopmanschap M.A. Economic valuation of informal care. An overview of methods and applications. Eur. J. Hlth Econ. 2004; 5: 36-45.

284

Koopmanschap M.A. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert. Rev. Pharmacoeconom. Outcomes Res. 2005; 5: 23-28.

285

Koopmanschap M.A., Rutten F.F., van Ineveld B.M., van Roijen L. The friction cost method for measuring indirect costs of disease. J. Hlth Econ. 1995; 14: 171-189.

286

Ramsey S.D., Patrick D.L., Albert R.K. et al.The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group. Chest 1995; 108: 1594-1601.

287

Al M.J., Koopmanschap M.A., van Enckevort P.J. et al. Cost-effectiveness of lung transplantation in the Netherlands: a scenario analysis. Chest 1998; 113: 124-130.

288

Groen H., van der B.W., Koeter G.H., TenVergert E.M. Cost-effectiveness of lung transplantation in relation to type of end-stage pulmonary disease. Am. J. Transplant. 2004; 4: 1155-1162.

289

Ramsey S.D., Berry K., Etzioni R. et al. Cost-effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N. Engl. J. Med. 2003; 348: 2092-2102.

290

Anon J.M., Garcia de Lorenzo A., Zarazaga A. et al. Mechanical ventilation of patients on longterm oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis. Intensive Care Med. 1999; 25: 452-457.

291

Goldstein R.S., Gort E.H., Guyatt G.H., Feeny D. Economic analysis of respiratory rehabilitation. Chest 1997; 112: 370-379.

292

Griffiths T.L., Phillips C.J., Davies S. et al. Cost-effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax 2001; 56: 779-784.

293

Hoogendoorn M., Rutten-van Mölken M.P., Hoogenveen R.T. et al. A dynamic population model of disease progression in COPD. Eur. Respir. J. 2005; 26: 223-233.

294

van den B.G., Rutten-van Mölken M.P., Folgering H. et al. The economic effects of screening for obstructive airway disease: an economic analysis of the DIMCA program. Prev. Med. 2000; 30: 302-308.

295

Oostenbrink J.B., Rutten-van Mölken M.P., Al M.J. et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 23: 241-249.

296

van Hout B.A., Al M.J., Gordon G.S., Rutten F.F. Costs, effects and C / E-ratios alongside a clinical trial. Hlth Econ. 1994; 3: 309-319.

297

Briggs A., Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Hlth Econ. 1998; 7: 723-740.

298

Briggs A.H., Wonderling D.E., Mooney C.Z. Pulling cost-effectiveness analysis up by its bootstraps: a nonparametric approach to confidence interval estimation. Hlth Econ. 1997; 6: 327-340.

299

Langley P.C. The NICE reference case requirement: implications for drug manufacturers and health systems. Pharmacoeconomics 2004; 22: 267-271.

300

Fenwick E., Claxton K., Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Hlth Econ. 2001; 10: 779-787.

301

Sin D.D., Golmohammadi K., Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am. J. Med. 2004; 116: 325-331.

302

Borg S., Ericsson A., Wedzicha J. et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Hlth 2004; 7: 153-167.

303

Oostenbrink J.B., Rutten-van M#ölken M.P., Monz B.U., FitzGerald J.M. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Hlth 2005; 8: 32-46.

304

Spencer M., Briggs A.H., Grossman R.F., Rance L. Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23: 619-637.

305

Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.

306

Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 709-721.

307

Miniati M., Filippi E., Falaschi F. et al. Radiologic evaluation of emphysema in patients with chronic obstructive pulmonary disease. Chest radiography versus high resolution computed tomography. Am. J. Respir. Crit. Care Med. 1995; 151: 1359-1367.

308

Kinsella M., Muller N.L., Staples C. et al. Hyperinflation in asthma and emphysema. Assessment by pulmonary function testing and computed tomography. Chest 1988; 94: 286-289.

309

Morrison N.J., Abboud R.T., Ramadan F. et al. Comparison of single breath carbon monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am. Rev. Respir. Dis. 1989; 139: 1179-1187.

310

Parr D.G., Stoel B.C., Stolk J., Stockley R.A. Validation of computed tomographic lung densitometry for monitoring emphysema in a1-antitrypsin deficiency. Thorax 2006; 61: 485-490.

311

Biernacki W., Ryan M., MacNee W., Flenley D.C. Can the quantitative CT scan detect progression of emphysema? Am. Rev. Respir. Dis. 1989; 131: A120.

312

Dirksen A., Dijkman J.H., Madsen F. et al. A randomized clinical trial of a1-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999; 160: 1468-1472.

313

Dowson L.J., Guest P.J., Stockley R.A. Longitudinal changes in physiological, radiological, and health status measurements in a1-antitrypsin deficiency and factors associated with decline. Am. J. Respir. Crit. Care Med. 2001; 164: 1805-1809.

314

Soejima K., Yamaguchi K., Kohda E. et al. Longitudinal follow-up study of smoking-induced lung density changes by high-resolution computed tomography. Am. J. Respir. Crit. Care Med. 2000; 161: 1264-1273.

315

Nakano Y., Muro S., Sakai H. et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am. J. Respir. Crit. Care Med. 2000; 162: 1102-1108.

316

Orlandi I., Moroni C., Camiciottoli G. et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 604-610.

317

Nakano Y., Muller N.L., King G.G. et al. Quantitative assessment of airway remodeling using high-resolution CT. Chest 2002; 122 (suppl. 6): 271S-275S.

318

O'Donnell R.A., Peebles C., Ward J.A. et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.

319

Hayhurst M.D., MacNee W., Flenley D.C. et al. Diagnosis of pulmonary emphysema by computerised tomography. Lancet 1984; 2: 320-322.

320

Guenard H., Diallo M.H., Laurent F., Vergeret J. Lung density and lung mass in emphysema. Chest 1992; 102: 198-203.

321

Haraguchi M., Shimura S., Hida W., Shirato K. Pulmonary function and regional distribution of emphysema as determined by high-resolution computed tomography. Respiration 1998; 65: 125-129.

322

Heremans A., Verschakelen J.A., Van Fraeyenhoven L., Demedts M. Measurement of lung density by means of quantitative CT scanning. A study of correlations with pulmonary function tests. Chest 1992; 102: 805-811.

323

Hartley P.G., Galvin J.R., Hunninghake G.W. et al. Highresolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J. Appl. Physiol. 1994; 76: 271-277.

324

Rienmuller R.K., Behr J., Kalender W.A. et al. Standardized quantitative high resolution CT in lung diseases. J. Comput. Assist. Tomogr. 1991; 15: 742-749.

325

Gould G.A., MacNee W., McLean A. et al. CT measurements of lung density in life can quantitate distal airspace enlargement - an essential defining feature of human emphysema. Am. Rev. Respir. Dis. 1988; 137: 380-392.

326

Gould G.A., Redpath A.T., Ryan M. et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur. Respir. J. 1991; 4: 141-146.

327

Dirksen A., Friis M., Olesen K.P. et al. Progress of emphysema in severe a1-antitrypsin deficiency as assessed by annual CT. Acta Radiol. 1997; 38: 826-832.

328

Bankier A.A., De Maertelaer V., Keyzer C., Gevenois P.A. Pulmonary emphysema: subjective visual grading versus objective quantification with macroscopic morphometry and thin-section CT densitometry. Radiology 1999; 211: 851-858.

329

Gevenois P.A., De Maertelaer V., De Vuyst P. et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 1995; 152: 653-657.

330

Gevenois P.A, De Vuyst P., Sy M. et al. Pulmonary emphysema: quantitative CT during expiration. Radiology 1996; 199: 825-829.

331

Gevenois P.A., De Vuyst P., De Maertelaer V. et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am. J. Respir. Crit. Care Med. 1996; 154: 187-192.

332

Muller N.L., Staples C.A., Miller R.R., Abboud R.T. ''Density mask''. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782-787.

333

Dowson L.J., Guest P.J., Hill S.L. et al. High-resolution computed tomography scanning in a1-antitrypsin deficiency: relationship to lung function and health status. Eur. Respir. J. 2001; 17: 1097-1104.

334

Parr D.G., Stoel B.C., Stolk J., Stockley R.A. Pattern of emphysema distribution in a1-antitrypsin deficiency influences lung function impairment. Am. J. Respir. Crit. Care Med. 2004; 170: 1172-1178.

335

Kinsella M., Muller N.L., Abboud R.T. et al. Quantitation of emphysema by computed tomography using a ''density mask'' program and correlation with pulmonary function tests. Chest 1990; 97: 315-321.

336

Park K.J., Bergin C.J., Clausen J.L. Quantitation of emphysema with three-dimensional CT densitometry: comparison with two-dimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999; 211: 541-547.

337

Nakano Y., Wong J.C., de Jong P.A. et al. The prediction of small airway dimensions using computed tomography. Am. J. Respir. Crit. Care Med. 2005; 171: 142-146.

338

King G.G., Muller N.L., Whittall K.P. et al. An analysis algorhythm for measuring airway lumen and wall areas from high-resolution computed tomographic data. Am. J. Respir. Crit. Care Med. 2000; 161: 574-580.

339

Berger P., Perot V., Desbarats P. et al. Airway wall thickness in cigarette smokers: quantitative thin-section CT assessment. Radiology 2005; 235: 1055-1064.

340

Matsuoka S., Kurihara Y., Nakajima Y. et al. Serial change in airway lumen and wall thickness at thin-section CT in asymptomatic subjects. Radiology 2005; 234: 595-603.

341

Brillet P.Y., Fetita C.I., Beigelman-Aubry C. et al. Quantification of bronchial dimensions at MDCT using dedicated software. Eur. Radiol. 2007; 17: 1483-1489.

342

Kemerink G.J., Lamers R.J., Thelissen G.R., Van Engelshoven J.M. CT densitometry of the lungs: scanner performance. J. Comput. Assist. Tomogr. 1996; 20: 24-33.

343

Parr D.G., Stoel B.C., Stolk J. et al. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am. J. Respir. Crit. Care Med. 2004; 170: 883-890.

344

Kemerink G.J., Lamers R.J., Thelissen G.R., Van Engelshoven J.M. The nonlinear partial volume effect and computed tomography densitometry of foam and lung. Med. Phys. 1995; 22: 1445-1450.

345

Van Dyk J., Keane T.J., Rider W.D. Lung density as measured by computerized tomography: implications for radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 1363-1372.

346

Wegener O.H., Koeppe P., Oeser H. Measurement of lung density by computed tomography. J. Comput. Assist. Tomogr. 1978; 2: 263-273.

347

Kalender W.A., Rienmuller R., Seissler W. et al. Measurement of pulmonary parenchymal attenuation: use of spirometric gating with quantitative CT. Radiology 1990; 175: 265-268.

348

Gierada D.S., Yusen R.D., Pilgram T.K. et al. Repeatability of quantitative CT indexes of emphysema in patients evaluated for lung volume reduction surgery. Radiology 2001; 220: 448-454.

349

Hoffman E.A., McLennan G. Assessment of the pulmonary structure-function relationship and clinical outcomes measures: quantitative volumetric CT of the lung. Acad. Radiol. 1997; 4: 758-776.

350

Shaker S.B., Dirksen A., Laursen L. et al. Volume adjustment of lung density by computed tomography scans in patients with emphysema. Acta Radiol. 2004; 45: 417-423.

351

Stolk J., Dirksen A., van der Lugt A.A. et al. Repeatability of lung density measurements with low-dose computed tomography in subjects with a1-antitrypsin deficiencyassociated emphysema. Invest. Radiol. 2001; 36: 648-651.

352

Lamers R.J., Kemerink G.J., Drent M., Van Engelshoven J.M. Reproducibility of spirometrically controlled CT lung densitometry in a clinical setting. Eur. Respir. J. 1998; 11: 942-945.

353

Moroni C., Mascalchi M., Camiciottoli G. et al. Comparison of spirometric-gated and -ungated HRCT in COPD. J. Comput. Assist. Tomogr. 2003; 27: 375-379.

354

Newell J.D., Hogg J.C., Snider G.L. Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema. Eur. Respir. J. 2004; 23: 769-775.

355

Robinson P.J., Kreel L. Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J. Comput. Assist. Tomogr. 1979; 3: 740-748.

356

Siegelman S. Pulmonary system: Practical approaches to pulmonary diagnosis. New York: Grune and Stratton; 1979.

The authors declare that there are no conflicts of interest present.